改良LMB89 C组方案治疗儿童高危伯基特淋巴瘤的临床分析
该回顾性研究分析了2007年至2017年接受改良LMB89 C组方案治疗的172例初治高危儿童伯基特淋巴瘤,全组3年OS率为88.9%,3年EFS率为87.9%。C3组3年EFS率显著低于C1和C2组,且C3组中联合利妥昔单抗者的3年EFS率优于单纯化疗者。
要点
- 改良LMB89 C组方案对高危儿童伯基特淋巴瘤疗效理想,全组3年EFS率达87.9%。
- C3组预后显著差于C1和C2组,3年EFS率仅73.4%。
- C3组中联合利妥昔单抗可显著改善3年EFS率(79.3%对44.4%)。
核心结论
- 改良LMB89 C组方案对于高危儿童伯基特淋巴瘤具有较理想的疗效。
研究设计与样本
- 回顾性分析2007年1月至2017年4月接受改良LMB89 C组方案治疗的172例初治高危伯基特淋巴瘤患儿。
主要发现
- 全组中位随访36.0个月,3年OS率为(88.9±2.4)%,3年EFS率为(87.9±2.6)%。
- C1、C2、C3组3年EFS率分别为(96.9±2.1)%、(90.9±3.9)%、(73.4±6.5)%,C3组低于C1组(P=0.001)和C2组(P=0.036)。
- C3组中利妥昔单抗联合化疗与单纯化疗的3年EFS率分别为(79.3±6.8)%和(44.4±16.6)%(P=0.015)。
- 多因素分析显示,临床分期Ⅳ期(包括白血病期)和中期评估有瘤灶为预后不良的独立危险因素[HR=4.241(95%CI 1.163~27.332),P=0.026;HR=32.184(95%CI 11.441~99.996),P<0.001]。
- 治疗相关死亡率为2.9%,10例进展死亡,5例复发。
临床怎么用
- 对于高危儿童伯基特淋巴瘤,可采用改良LMB89 C组方案治疗。
- C3组患者应优先考虑联合利妥昔单抗以改善生存。
- 临床分期Ⅳ期及中期评估有瘤灶提示预后不良,需加强治疗或监测。
局限性
- 本研究为单中心回顾性分析,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the therapeutic effect of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma. Methods: The clinical data of 172 children with newly diagnosed high-risk Burkitt lymphoma from January 2007 to April 2017 were retrospectively analyzed. All the cases were treated with the modified LMB89 Group C regimen. Results: The median age of the patients was 6 (1-14) years. The sex ratio was 5.1∶1, 144 boys (83.7%) and 28 girls (16.3%) . According to St. Jude staging classification, 2 patients (1.2%) were in stage Ⅱ, 54 (31.4%) in stage Ⅲ and 116 (67.4%) in stage Ⅳ. Of them, 46 patients (26.7%) had mature B cell acute lymphoblastic leukemia (B-ALL) , and 52 patients had central nervous system (CNS) involvement. According to risk group, the patients can be divided into group C1 (CNS1, without testicles/ovaries involvement, n=65) , group C2 (CNS2, testicles/ovaries involvement, n=55) and group C3 (CNS3, n=52) . A total of 145 patients received rituximab combined with chemotherapy during the treatment, 10 patients suffered from progressive disease and died, and 5 patients relapsed. Treatment-related mortality was 2.9%. With a median follow-up of 36.0 (0.5-119.0) months, 3-year overall survival (OS) rate was (88.9±2.4) % and event free survival (EFS) rate was (87.9±2.6) % for all patients. 3-year EFS rates were (96.9±2.1) %, (90.9±3.9) % and (73.4±6.5) % for Group C1, C2 and C3 respectively, and that of Group C3 was significantly lower than that of Group C1 (χ(2)=12.939, P=0.001) and Group C2 (χ(2)=6.302, P=0.036) . The 3-year EFS rates were (79.3±6.8) % and (44.4±16.6) % for patients in group C3 treated with chemotherapy combined with rituximab and chemotherapy alone (χ(2)=5.972, P=0.015) . Multivariable Cox regression analysis showed that Stage Ⅳ (including B-ALL) , residual diseases in mid-term evaluation were independent unfavorable prognostic factors[HR=4.241 (95%CI 1.163-27.332) , P=0.026; HR=32.184 (95%CI 11.441-99.996) , P<0.001]. Conclusions: The modified LMB89 Group C regimen has ideal effect for the children with high-risk Burkitt lymphoma. 目的: 分析改良LMB 89 C组方案治疗高危儿童伯基特淋巴瘤的疗效。 方法: 对2007年1月至2017年4月接受改良LMB 89 C组方案治疗的172例初治高危伯基特淋巴瘤患儿进行回顾性分析。 结果: 全部172例患儿中位发病年龄6(1~14)岁,男144例(83.7%),女28例(16.3%),St.Jude分期Ⅱ、Ⅲ、Ⅳ期分别为2例(1.2%)、54例(31.4%)、116例(67.4%),46例(26.7%)为白血病期,52例(30.2%)存在中枢神经系统(CNS)侵犯。危险度分组:C1组(CNS1,无睾丸/卵巢侵犯)65例,C2组[CNS2和(或)睾丸/卵巢侵犯]55例,C3组(CNS3)52例。145例联合应用利妥昔单抗。10例未缓解并进展至死亡,5例复发,治疗相关死亡率为2.9%。中位随访时间36.0(0.5~119.0)个月,全组3年总生存(OS)率为(88.9±2.4)%、3年无事件生存(EFS)率为(87.9±2.6)%。C1、C2、C3组3年EFS率分别为(96.9±2.1)%、(90.9±3.9)%、(73.4±6.5)%,C3组低于C1组(χ(2)=12.939,P=0.001)和C2组(χ(2)=6.302,P=0.036)。C3组中利妥昔单抗联合化疗、单纯化疗患儿的3年EFS率分别为(79.3±6.8)%、(44.4±16.6)%(χ(2)=5.972,P=0.015)。多因素分析结果显示,临床分期Ⅳ期(包括白血病期)、中期评估有瘤灶为预后不良的危险因素[HR=4.241(95%CI 1.163~27.332),P=0.026;HR=32.184(95%CI 11.441~99.996),P<0.001]。 结论: 改良LMB 89 C组方案对于高危儿童伯基特淋巴瘤具有较理想的疗效。.
引用
- Zhang M, Jin L, Yang J, et al. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31495128. doi:10.3760/cma.j.issn.0253-2727.2019.08.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。